Clinical Studies on the Efficacy of Agomelatine on Depressive Symptoms

Goodwin, Guy M.
September 2009
CNS Drugs;2009 Supplement 2, p35
Academic Journal
The novel mechanism of action of agomelatine, with affinity for melatonergic and 5-HT2C receptors, offers the prospect of efficacy in major depression and anxiety with minimal adverse effects. The challenge of performing acute placebo-controlled treatment trials in a relevant sample of patients with moderate to severe major depression is considerable. The efficacy of active treatment may be obscured by excessive responses in placebo and active treatment arms. The agomelatine programme has successfully introduced methodological innovation to overcome this risk and ensure that cases of major depression display adequate severity on both ratings of symptoms and measures of functional impairment. The efficacy of agomelatine in major depression has thus been demonstrated at doses of 25-50 mg against the full range of symptoms that make up the depressive syndrome in patients with moderate to severe major depression.


Related Articles

  • Depression: A Special Report. Moring, Mark // Campus Life;Nov/Dec2001, Vol. 60 Issue 4, p54 

    Evaluates the information about depression. Diagnosis of depressed patient; Characteristics and description of depressed person; Causes of depression; Religious perspective and advice regarding depression.

  • The PHQ-9. Kroenke, Kurt; Spitzer, Robert L.; Williams, Janet B. W. // JGIM: Journal of General Internal Medicine;Sep2001, Vol. 16 Issue 9, p606 

    OBJECTIVE: While considerable attention has focused on improving the detection of depression, assessment of severity is also important in guiding treatment decisions. Therefore, we examined the validity of a brief, new measure of depression severity. MEASUREMENTS: The Patient Health...

  • Clinical Review of Recent Findings on the Awareness, Diagnosis and Treatment of Depression. Preboth, Monica // American Family Physician;5/15/2000, Vol. 61 Issue 10, p3158 

    Presents the results of a clinical review conducted by the Council on Scientific Affairs of the American Medical Association on the diagnosis and management of depression. Findings on epidemiology, burden and comorbidity; Barriers to the recognition, diagnosis and management of depression;...

  • Effects of hypnotics on anxious patients. Malpas, Ann; Legg, N. J.; Scott, D. F.; Malpas, A // British Journal of Psychiatry;May74, Vol. 124, p482 

    The article examines the effect of hypnotics on anxious out-patients. The behavioral and electroencephalogram (EEG) measures were used to determine whether persistent effects to ten anxious female out-patients, that range from 9 to 57 years old, were present after a seven-day treatment of...

  • Race and depression. Kales, Helen C.; Mellow, Alan M.; Neugroschi, Judith A. // Geriatrics;May2006, Vol. 61 Issue 5, p18 

    While It Is recognized that medical and neurological comorbidities complicate the accurate diagnosis end treatment of late-life depression, the possibility that patient race or even gender may affect management decisions Is less discussed. This article reviews the current literature on racial...

  • Placebo Response of Non-Pharmacological and Pharmacological Trials in Major Depression: A Systematic Review and Meta-Analysis. Brunoni, AndrĂ© Russowsky; Lopes, Mariana; Kaptchuk, Ted J.; Fregni, Felipe // PLoS Clinical Trials;Mar2009, Vol. 6 Issue 3, Special section p1 

    Background: Although meta-analyses have shown that placebo responses are large in Major Depressive Disorder (MDD) trials; the placebo response of devices such as repetitive transcranial magnetic stimulation (rTMS) has not been systematically assessed. We proposed to assess placebo responses in...

  • Placebo run-in period in studies of depressive disorders. Clinical, heuristic and research implications. Quitkin, F. M.; McGrath, P. J.; Stewart, J. W.; Ocepek-Welikson, K.; Taylor, B. P.; Nunes, E.; Delivannides, D.; Agosti, V.; Donovan, S. J.; Ross, D.; Petkova, E.; Klein, D. F. // British Journal of Psychiatry;Sep98, Vol. 173, p242 

    Background: In spite of the virtually ubiquitous nature of the initial 10-day placebo run-in period (IPR) in drug trials, there is little empirical data establishing its relevance.Method: Data from 593 subjects were examined retrospectively to determine whether or not...

  • A double-blind trial of intravenous thyrotrophin-releasing hormone in the treatment of reactive depression. Evans, L. E. J.; Hunter, P.; Hall, R.; Johnston, Moira; Roy, V. Mathew; Evans, L E; Johnston, M; Roy, V M // British Journal of Psychiatry;Sep75, Vol. 127, p227 

    In a double-blind trial 600 mug. of thyrotrophin-releasing hormone (TRH) was compared with placebo given daily for four days to two groups of ten patients. There was no significant difference between the antidepressant effects of TRH and placebo.

  • Evaluation and Management of Geriatric Depression in Primary Care. Lapid, Maria I.; Rummans, Teresa A. // Mayo Clinic Proceedings;Nov2003, Vol. 78 Issue 11, p1423 

    Geriatric depression is a common but frequently unrecognized or inadequately treated condition in the elderly population. Manifestations of major depression in elderly persons may hinder early detection; anxiety, somatic complaints, cognitive impairment, and concurrent medical and neurologic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics